Neuroblastoma: Molecular Pathogenesis and Therapy

Overview

Journal Annu Rev Med

Publisher Annual Reviews

Specialty General Medicine

Date 2014 Nov 12

PMID 25386934

Citations 167

Authors

Chrystal U Louis

Jason M Shohet

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is a developmental tumor of young children arising from the embryonic sympathoadrenal lineage of the neural crest. Neuroblastoma is the primary cause of death from pediatric cancer for children between the ages of one and five years and accounts for ∼13% of all pediatric cancer mortality. Its clinical impact and unique biology have made this aggressive malignancy the focus of a large concerted translational research effort. New insights into tumor biology are driving the development of new classification schemas. Novel targeted therapeutic approaches include small-molecule inhibitors as well as epigenetic, noncoding-RNA, and cell-based immunologic therapies. In this review, recent insights regarding the pathogenesis and biology of neuroblastoma are placed in context with the current understanding of tumor biology and tumor/host interactions. Systematic classification of patients coupled with therapeutic advances point to a future of improved clinical outcomes for this biologically distinct and highly aggressive pediatric malignancy.

Citing Articles

Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.

Sharma R, Yadav J, Bhat S, Musayev A, Myrzagulova S, Sharma D Mol Neurobiol. 2025; .

PMID: 39804528 DOI: 10.1007/s12035-024-04680-w.

Advances in multimodal imaging for adrenal gland disorders: integrating CT, MRI, and nuclear medicine.

Yokoyama K, Matsuki M, Isozaki T, Ito K, Imokawa T, Ozawa A Jpn J Radiol. 2025; .

PMID: 39794659 DOI: 10.1007/s11604-025-01732-6.

Regulation and Function of CCL2 and N-Myc in Retinoic Acid-treated Neuroblastoma Cells.

Murra N, Pommert N, Schmidt B, Issa R, Kaehler M, Bruckmueller H Cancer Genomics Proteomics. 2024; 22(1):90-102.

PMID: 39730182 PMC: 11696317. DOI: 10.21873/cgp.20490.

Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics.

Ren K, Wang Y, Zhang M, Tao T, Sun Z Children (Basel). 2024; 11(11).

PMID: 39594898 PMC: 11593200. DOI: 10.3390/children11111323.

Systematic Analysis of miR-506-3p Target Genes Identified Key Mediators of Its Differentiation-Inducing Function.

Cardus D, Smith M, Vernaza A, Smith J, Del Buono B, Parajuli A Genes (Basel). 2024; 15(10).

PMID: 39457392 PMC: 11507652. DOI: 10.3390/genes15101268.

References

Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L . Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst. 2009; 101(22):1562-74. DOI: 10.1093/jnci/djp355. View

Maris J . Recent advances in neuroblastoma. N Engl J Med. 2010; 362(23):2202-11. PMC: 3306838. DOI: 10.1056/NEJMra0804577. View

Matthay K, Perez C, Seeger R, Brodeur G, Shimada H, Atkinson J . Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998; 16(4):1256-64. DOI: 10.1200/JCO.1998.16.4.1256. View

Westermann F, Muth D, Benner A, Bauer T, Henrich K, Oberthuer A . Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 2008; 9(10):R150. PMC: 2760877. DOI: 10.1186/gb-2008-9-10-r150. View

Heczey A, Louis C . Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov Med. 2013; 16(90):287-94. PMC: 4106238. View

Di Lascio S, Bachetti T, Saba E, Ceccherini I, Benfante R, Fornasari D . Transcriptional dysregulation and impairment of PHOX2B auto-regulatory mechanism induced by polyalanine expansion mutations associated with congenital central hypoventilation syndrome. Neurobiol Dis. 2012; 50:187-200. DOI: 10.1016/j.nbd.2012.10.019. View

Minuti G, DIncecco A, Landi L, Cappuzzo F . Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin Pharmacother. 2014; 15(9):1203-13. DOI: 10.1517/14656566.2014.909412. View

Ara T, Nakata R, Sheard M, Shimada H, Buettner R, Groshen S . Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res. 2013; 73(13):3852-64. PMC: 3740971. DOI: 10.1158/0008-5472.CAN-12-2353. View

Shtukmaster S, Schier M, Huber K, Krispin S, Kalcheim C, Unsicker K . Sympathetic neurons and chromaffin cells share a common progenitor in the neural crest in vivo. Neural Dev. 2013; 8:12. PMC: 3693940. DOI: 10.1186/1749-8104-8-12. View

10.

Trochet D, Bourdeaut F, Janoueix-Lerosey I, Deville A, De Pontual L, Schleiermacher G . Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet. 2004; 74(4):761-4. PMC: 1181953. DOI: 10.1086/383253. View

11.

Prasad M, Sauka-Spengler T, Labonne C . Induction of the neural crest state: control of stem cell attributes by gene regulatory, post-transcriptional and epigenetic interactions. Dev Biol. 2012; 366(1):10-21. PMC: 3354335. DOI: 10.1016/j.ydbio.2012.03.014. View

12.

Kim E, Shohet J . Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis. J Natl Cancer Inst. 2009; 101(22):1527-9. DOI: 10.1093/jnci/djp376. View

13.

Newhart A, Rafalska-Metcalf I, Yang T, Negorev D, Janicki S . Single-cell analysis of Daxx and ATRX-dependent transcriptional repression. J Cell Sci. 2012; 125(Pt 22):5489-501. PMC: 3561858. DOI: 10.1242/jcs.110148. View

14.

Burton P, Walls J . A selection adjusted comparison of hospitalization on continuous ambulatory peritoneal dialysis and haemodialysis. J Clin Epidemiol. 1989; 42(6):531-9. DOI: 10.1016/0895-4356(89)90149-2. View

15.

Ostler K, Yang Q, Looney T, Zhang L, Vasanthakumar A, Tian Y . Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Res. 2012; 72(18):4714-23. PMC: 3445765. DOI: 10.1158/0008-5472.CAN-12-0886. View

16.

De Bernardi B, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R . Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer. 2008; 99(7):1027-33. PMC: 2567095. DOI: 10.1038/sj.bjc.6604640. View

17.

Burney M, Johnston C, Wong K, Teng S, Beglopoulos V, Stanton L . An epigenetic signature of developmental potential in neural stem cells and early neurons. Stem Cells. 2013; 31(9):1868-80. DOI: 10.1002/stem.1431. View

18.

Fredlund E, Ringner M, Maris J, Pahlman S . High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A. 2008; 105(37):14094-9. PMC: 2544584. DOI: 10.1073/pnas.0804455105. View

19.

Rinon A, Molchadsky A, Nathan E, Yovel G, Rotter V, Sarig R . p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. Development. 2011; 138(9):1827-38. DOI: 10.1242/dev.053645. View

20.

Betters E, Liu Y, Kjaeldgaard A, Sundstrom E, Garcia-Castro M . Analysis of early human neural crest development. Dev Biol. 2010; 344(2):578-92. PMC: 2927129. DOI: 10.1016/j.ydbio.2010.05.012. View